Anti-tumor vaccine
OwnerBill Minshall, Suzanne Minshall +2inventors
InventorsBill Minshall, Suzanne Minshall, Michael Skotzko, John Conner
Life of this patent
Estimating the term…
Abstract
A therapeutic vaccine for the treatment of melanoma, mast cell tumors and sarcoma in mammals. The vaccine preferably comprises at least one allogenic cell line providing at least one, and preferably two or more gangliosides selected from the group consisting of GD-2, GD-3, GM-2, GM-3, GD-1b and GT-1b. At least one cytokine selected from the group consisting of GM-CSF, IL-2, IL-4, and IL-12 and at least one heat shock protein selected from the group consisting of HSP-60, HSP-70 and HSP-90 are added as adjuvants. A bacterial organism may further be added as an adjuvant.
Claims39
A composition for inducing an immune response in a mammal to solid tumor associated antigens, the composition comprising:
- (a) at least one allogenic line of cancer cells providing at least one tumor-associated ganglioside selected from the group consisting of GD-2, GD-3, GM-2, GM-3, GD-1b, and GT-1b;
- (b) at least one cytokine selected from the group consisting of GM-CSF, IL-2, IL-4, IL-12 and TNF∝;
- and
- (c) at least one heat shock protein selected from the group consisting of HSP-60, HSP-70 and HSP-90.
A method of inducing a systemic immune response in a mammal to solid tumor associated antigens, the method comprising the steps:
- (a) providing cells of at least one allogenic cell line providing at least one tumor-associated ganglioside, selected from the group consisting of GD-2, GD-3, GM-2, GM-3, GD-1b, and GT-1b;
- (b) providing at least one cytokine selected from the group consisting of GM-CSF, IL-2, IL-4, IL-12 and TNF∝;
- (c) providing at least one heat shock protein selected from the group consisting of HSP-60, HSP-70 and HSP-90;
- and
- (d) concurrently administering an effective number of cells in step (a), an effective amount of said cytokine in step (b), and an effective amount of said heat shock protein in step (c) to said mammal, said administration thereby inducing a systemic immune response specific to said antigens.
The method of claim 31 wherein said bacterial adjuvant comprises BCG.
Dependencies are inferred from the claim text.